Endocrinology 166:bqaf028 Kaur M, Misra S (2024) A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
(2) Patients with major heart, liver, kidney, and other organ disorders, including co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV), or other chronic liver diseases such as alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and autoimmune hepatitis
Potential interactions have been reported in the literature involving diabetes medications, blood pressure medications, and certain other drugs
Fortunately, this is a temporary side effect and typically resolves within a few minutes to a few hours after the treatment